


# PRODUCT INFORMATION



## Fondaparinux (sodium salt)

Item No. 24033

**CAS Registry No.:** 114870-03-0  
**Formal Name:** methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 4)-O- $\beta$ -D-glucopyranuronosyl-(1 $\rightarrow$ 4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 4)-O-2-O-sulfo- $\alpha$ -L-idopyranuronosyl-(1 $\rightarrow$ 4)-2-deoxy-2-(sulfoamino)- $\alpha$ -D-glucopyranoside, 6-(hydrogen sulfate), decasodium salt SR 90107A  
**Synonym:** SR 90107A  
**MF:** C<sub>31</sub>H<sub>43</sub>N<sub>3</sub>O<sub>49</sub>S<sub>8</sub> • 10Na  
**FW:** 1,728.0  
**Purity:**  $\geq$ 95%  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:**  $\geq$ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Fondaparinux (sodium salt) is supplied as a solid. Aqueous solutions of fondaparinux (sodium salt) can be prepared by directly dissolving the solid in aqueous buffers. The solubility of fondaparinux (sodium salt) in PBS (pH 7.2) is approximately 10 mg/ml. We do not recommend storing the aqueous solution for more than one day.

### Description

Fondaparinux is a pentasaccharide inhibitor of Factor Xa, the enzyme that activates prothrombin in the coagulation cascade (IC<sub>50</sub>s = 40, 45, and 36 nM for human, rabbit, and rat enzymes, respectively, *in vitro*).<sup>1</sup> It binds to antithrombin III (K<sub>d</sub>s = 48, 132, 78, and 50 nM for human, rabbit, baboon, and rat, respectively) and inhibits thrombin generation through the extrinsic and intrinsic routes (IC<sub>50</sub>s = 0.3 and 2.8  $\mu$ M, respectively). Fondaparinux dose-dependently inhibits thrombus formation in a rabbit model of venous thrombosis with complete inhibition of clot formation at a dose of 200  $\mu$ g/kg. Formulations containing fondaparinux have been used for prophylaxis of deep vein thrombosis following hip or knee replacement surgery.

### Reference

1. Herbert, J.M., Petitou, M., Lormeau, J.C., *et al.* SR 90107A/Org 31540, a novel anti-factor Xa antithrombotic agent. *Cardiovasc. Drug Rev.* **15**(1), 1-26 (1997).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/05/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM